insulin vs glp-1 Receptor Agonists as Treatments for Type 2 Diabetes The dual glucose-dependent insulinotropic polypeptide

They suppress appetite, slow gastric emptying (how quickly food leaves your stomach), enhance insulin release when sugar is present, reduce glucagon (a hormone that raises blood sugar), and produce significant weight loss and better blood sugar control in clinical trials

Glucagon-like peptide-1 7-36: a physiological incretin in man

Imaging and biomarker panels are used to characterize shifts in body composition alongside weight trajectories

The study showed that orforglipron led to significant weight changes in participants, especially at the highest dose

It is an investigational triple-receptor agonist that simultaneously targets the GLP-1, GIP, and glucagon receptors pathways involved in glucose regulation, energy balance, and metabolic homeostasis

There is also a powerful psychological benefit: as patients begin to see sculpting in areas that once felt hopeless, motivation grows and long-term commitment becomes easier and more enjoyable